Latest Information Update: 26 Jun 1998
At a glance
- Originator Teva Pharmaceutical Industries
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 26 Jun 1998 Discontinued-Preclinical for Neurological disorders in Israel (Unknown route)
- 05 Jun 1998 Preclinical development for Neurological disorders in Israel (Unknown route)